Need professional-grade analysis? Visit stockanalysis.com
$2.03B
N/A
624
N/A
Adaptive Biotechnologies Corp (ADPT) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $14.21, down 1.80% from the previous close.
Over the past year, ADPT has traded between a low of $7.36 and a high of $20.46. The stock has gained 92.5% over this period. It is currently 30.5% below its 52-week high.
Adaptive Biotechnologies Corp has a market capitalization of $2.03B.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Side-by-side comparison against top Healthcare peers.